Nanomaterials: Breaking through the bottleneck of tumor immunotherapy

Int J Biol Macromol. 2023 Mar 1:230:123159. doi: 10.1016/j.ijbiomac.2023.123159. Epub 2023 Jan 5.

Abstract

Immunotherapy exerts its excellent anti-tumor effects by stimulating and enhancing the immune response of the body, and has become another important class of anti-tumor therapy besides chemotherapy, targeted therapy and radiotherapy. Various types of immunotherapeutic drugs have gained their clinical values, but the in vivo delivery of drugs still faces many challenges, such as poor tumor permeability and low tumor cell uptake rate. In recent years, owing to highly targeting properties, better biocompatibility, and easy functionalization, nanomaterials have been widely applicated in tumor treatment, especially in tumor immunotherapy. Furthermore, nanomaterials have large drug loading capacity, strong tumor targeting and easy modification, which can effectively overcome the drawbacks of traditional immunotherapy. This paper reviews the progress of nanomaterial-based tumor immunotherapy in recent years and provides a theoretical basis for exploring new nanomaterial-based tumor immunotherapy strategies.

Keywords: Immunotherapy; Nanomaterials; Targeted therapy; Tumor; Tumor microenvironment (TME).

Publication types

  • Review

MeSH terms

  • Humans
  • Immunotherapy
  • Nanostructures* / therapeutic use
  • Neoplasms* / therapy
  • Tumor Microenvironment